SUMMARY Syncope is a common emergency of children and adolescents, which has serious influence on the quality of life. Neurally-mediated syncope, including postural tachycardia syndrome, vasovagal syncope, orthostatic hypotension and orthostatic hypertension, is the main cause of syncope in children and adolescents. The main manifestations of neurally-mediated syncope are diverse, such as dizziness, headache, chest tightness, chest pain, pale complexion, fatigue, pre-syncope and syncope. Although the clinical manifestations are similar, each subtype of syncope has its hemodynamic feature and optimal treatment option. The diagnosis rate of syncope in children has been greatly improved on account of the development of the diagnostic procedures and methods. In recent years, with the promotion of head-up tilt test and drug-provocated head-up tilt test, the hemodynamic classification of neurally-mediated syncope gets continually refined. In recent years, with the effort of clinicians, an appropriate diagnostic protocol for children with syncope has been established. The initial evaluation consists of history taking, physical examination, standing test and standard electrocardiography. After the initial evaluation, some patients could be diagnosed definitely, such as postural tachycardia syndrome, orthostatic hypotension, and situ-ational syncope. Those with a specific entity causing syncope need selective clinical and laboratory investi-gations. Patients for whom the cause of syncope remained undetermined should undergo head-up tilt test. The precise pathogenesis of neurally-mediated syncope is not entirely clear. In recent years, studies have shown that neurally-mediated syncope may be related to several factors, including hypovolemia, high catecholamine status, abnormal local vascular tension, decreased skeletal muscle pump activity and abnormal neurohumoral factors. Currently based on the possible pathogenesis, the individualized treatment of neurally-mediated syncope has also been studied in-depth. Generally, the management of neurally-mediated syncope includes non-pharmacological and pharmacological interventions. Patient education is the fundamental part above all. In addition to exercise training, the first-line treatments mainly include oral rehydration salts, beta adrenoreceptor blockers, and alpha adrenoreceptor agonists. By analyzing the patient’s physiological indexes and biomarkers before treatment, the efficacy of medication could be well predicted. The individualized treatment will become the main direction in the future researches.
[1] 杨锦艳, 王成, 田宏, 等.儿童一过性意识丧失基础疾病谱分析[J].国际儿科学杂志, 2014, 41(2): 195-197, 201.
[2] 中华医学会儿科学分会心血管学组,《中华儿科杂志》编辑委员会,北京医学会儿科学分会心血管学组等.儿童晕厥诊断指南(2016年修订版)[J].中华儿科杂志, 2016, 54(4): 246-250.
[3] Chen L, Li X, Todd O, et a1. A clinical manifestation-based prediction of haemedynamicpottems of orthostatic intolerance in children:a multi-centre study[J]. Cardiol Young, 2014,24(4): 649-653.
[4] Chen L, Zhang Q, Ingrid S, et a1. Aetiology and clinical characteristics of syncope in Chinese children[J].Acta Paediatr, 2007, 96(10): 1505-1510.
[5] 杜军保, 李万镇. 基础直立倾斜试验对儿童不明原因晕厥的诊断研究[J]. 中华儿科杂志, 1997, 35(6): 309-312.
[6] 张清友, 杜军保, 李万镇. 舌下含化硝酸甘油直立倾斜试验对儿童不明原因晕厥的诊断研究[J]. 中华儿科杂志, 2004,42(5): 71.
[7] 张清友, 杜军保, 李万镇. 儿童体位性心动过速综合征的临床特征及随访研究[J]. 中华儿科杂志, 2005, 43(3): 165-169.
[8] 赵娟,杨锦艳,金红芳,等.儿童直立性高血压的临床特征[J].中华儿科杂志, 2012, 50(11): 839-842.
[9] 蔺婧, 王瑜丽, 张清友,等. 儿童青少年晕厥疾病谱近30年变化及卫生经济学分析单中心报告[J]. 中国实用儿科杂志, 2016, 31(5): 350-355.
[10] Zhang Q, Du J, Wang C, et al. The diagnostic protocol in children and adolescents with syncope: a multi-centre prospective study[J].Acta Paediatr, 2009, 98(5): 879-884.
[11] 金红芳, 杨锦艳, 李雪迎, 等. 改良Calgary评分在儿童心源性晕厥和血管迷走性晕厥鉴别诊断中的意义[J]. 中华儿科杂志, 2012, 50(2): 117-120.
[12] Zhang Q, Zhu L, Wang C, et al. Value of history taking in children and adolescents with cardiac syncope[J]. Cardiol Young, 2013, 23(1): 54-60.
[13] Numata T, Abe H, Nagatomo T, et a1. Successful treatment of malignant neurocardiogenic syncope with repeated tilt training program [J]. JpnCirc J, 2000, 64(5): 406-409.
[14] 鲁雯馨,杜军保.体位性心动过速综合征患儿自主神经功能评价与锻炼的研究进展[J].中华儿科杂志, 2015, 53(2): 149-152.
[15] Lu W, Yan H, Wu S, et al. Electrocardiography-derived predictors for therapeutic response to treatment in children with postural tachycardia syndrome[J].J Pediatr, 2016, 176: 128-133.
[16] Hampton JL, Parry SW,Kenny RA, et al. Lower 24 hour urinary sodium concentrations are associated with more severe symptoms in subjects with vasovagal syncope[J]. Heart, 2004, 90(6): 687-688.
[17] Chu W, Wan C, Wu L, et al. Oral rehydration salts: an effective choice for the treatment of children with vasovagal syncope[J]. Pediatr Cardiol, 2015, 36(4): 867-872.
[18] Zhang Q, Liao Y, Tang C, et al. Twenty-four-hour urinary sodium excretion and postural orthostatic tachycardia syndrome[J]. J Pe-diatr, 2012, 161(2): 281-284.
[19] Li H, Wang Y, Liu P, et al. Body mass index (BMI) is associa-ted with the therapeutic response to oral rehydration solution in children with postural tachycardia syndrome[J].Pediatr Cardiol, 2016, 37(7): 1313-1318.
[20] Liao Y, Chen S, Liu X, et al. Flow-mediated vasodilation and endothelium function in children with postural orthostatic tachycardia syndrome [J]. Am J Cardiol, 2010, 106(3): 378-382.
[21] Zhang Q, Du J, Li Y. Endothelial function in children with vasovagal syncope via color Doppler flow imaging[J]. Chin J Pract Pediatr, 2005, 20(8): 482-484.
[22] Zhang Q, Du J, Tang C. The efficacy of midodrine hydrochloride in the treatment of children withvasovagal syncope [J].J Pediatr,2006, 149(6): 777-780.
[23] Zhang F, Li X, Ochs T, et al. Midregional pro-adrenomedullin as a predictor for therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome [J]. J Am Coll Cardiol, 2012, 60(4): 315-320.
[24] Liao Y, Yang J, Zhang F, et al. Flow-mediated vasodilation as a predictor of therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome[J].Am J Cardiol, 2013, 112(6): 816-820.
[25] Yang J, Zhao J, Du S, et al. Postural orthostatic tachycardia syndrome with increased erythrocytic hydrogen sulfide and response to midodrine hydrochloride[J]. J Pediatr, 2013, 163(4): 1169-1173.
[26] Zhao J, Tang C, Jin H, et al. Plasma copeptin and therapeutic effectiveness of midodrine hydrochloride on postural tachycardia syndrome in children [J]. J Pediatr, 2014, 165(2): 290-294.
[27] Thieben M, Sandroni P, Sletten D, et al. Postural orthostatic tachycardia syndrome: Mayo clinic experience [J]. Mayo Clin Proc, 2007, 82(3): 308-313.
[28] 张凤文, 廖莹, 李雪迎, 等.儿童体位性心动过速综合征美托洛尔和盐酸米多君治疗118例报告[J].中华儿科杂志, 2011, 49(6): 428-432.
[29] 廖莹, 李雪迎, 张燕舞, 等.β受体阻断剂治疗血管迷走性晕厥的Meta分析[J]. 北京大学学报(医学版), 2008, 40(6): 603-609.
[30] Zhang Q, Chen X, Li J, et al. Orthostatic plasma norepinephrine level as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome[J]. J Transl Med, 2014,12(1): 249.
[31] Zhao J, Du S, Yang J, et al. Usefulness of plasma copeptin as a biomarker to predict the therapeutic effectiveness of metoprolol for postural tachycardia syndrome in children[J].Am J Cardiol, 2014, 114(4): 601-615.
[32] 中华医学会儿科学分会心血管学组,《中华儿科杂志》编辑委员会.儿童晕厥诊断指南[J].中华儿科杂志, 2009, 47(2): 99-101.
